A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)

Stopped Study terminated early prior to completing targeted enrollment of participants \<6 months of age due to recruitment challenges.

Conditions

• Chemotherapy-Induced Nausea and Vomiting

Interventions

• DRUG: Experimental: aprepitant
• DRUG: Experimental: fosaprepitant
• DRUG: Comparator: ondansetron
• DRUG: Ondansetron
• DRUG: Dexamethasone

Sponsor

Merck Sharp & Dohme LLC